GALECTIN THERAPEUTICS INC — Director's Dealing 2021

Sep 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2021-09-17

Reporting Person: Uihlein Richard E (Director, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-17	Convertible Note	$8.64	A	1157407	Acquired	2025-09-17	Common Stock (1157407)	Direct

Footnotes

F1: Excludes interest that may accrue following issuance of the Note.

F2: The Note is convertible upon 60 days prior written notice by the noteholder.

F3: In consideration for the Convertible Note, the Reporting Person loaned ten million dollars to the Company.

F4: Represents the principal amount of the note payable.